S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NASDAQ:VRAY

ViewRay - VRAY Stock Forecast, Price & News

$3.36
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.30
$3.38
50-Day Range
$3.35
$4.81
52-Week Range
$2.39
$4.96
Volume
792,670 shs
Average Volume
1.37 million shs
Market Capitalization
$610.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

ViewRay MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
100.9% Upside
$6.75 Price Target
Short Interest
Bearish
4.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.08mentions of ViewRay in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$173,460 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.60) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

426th out of 1,005 stocks

Electromedical Equipment Industry

7th out of 24 stocks


VRAY stock logo

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

StockNews.com Begins Coverage on ViewRay (NASDAQ:VRAY)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
ViewRay to host Investor Day
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings
2/27/2023
Today
3/26/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRAY
Employees
267
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+100.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-107,330,000.00
Net Margins
-105.01%
Pretax Margin
-105.01%

Debt

Sales & Book Value

Annual Sales
$102.21 million
Book Value
$0.45 per share

Miscellaneous

Free Float
177,260,000
Market Cap
$610.85 million
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Scott William DrakeScott William Drake
    President, Chief Executive Officer & Director
  • Drew Hill
    Senior Vice President-Operations & Development
  • William Patrick Burke
    Chief Financial Officer & Executive Vice President
  • James F. Dempsey
    Chief Scientific Officer
  • Martin Fuss
    Chief Medical Officer













VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRAY shares.
View VRAY analyst ratings
or view top-rated stocks.

What is ViewRay's stock price forecast for 2023?

5 analysts have issued twelve-month price objectives for ViewRay's stock. Their VRAY share price forecasts range from $5.50 to $8.00. On average, they anticipate the company's share price to reach $6.75 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for VRAY
or view top-rated stocks among Wall Street analysts.

How have VRAY shares performed in 2023?

ViewRay's stock was trading at $4.48 on January 1st, 2023. Since then, VRAY shares have decreased by 25.0% and is now trading at $3.36.
View the best growth stocks for 2023 here
.

When is ViewRay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our VRAY earnings forecast
.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) announced its earnings results on Monday, February, 27th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The firm earned $34.70 million during the quarter, compared to analyst estimates of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 93.57% and a negative net margin of 105.01%. The company's revenue was up 70.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.16) earnings per share.

What ETFs hold ViewRay's stock?
What guidance has ViewRay issued on next quarter's earnings?

ViewRay updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127.76 million-$143.09 million, compared to the consensus revenue estimate of $136.01 million.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (9.19%), Neuberger Berman Group LLC (5.44%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.50%) and Silverarc Capital Management LLC (1.33%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends
.

How do I buy shares of ViewRay?

Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.36.

How much money does ViewRay make?

ViewRay (NASDAQ:VRAY) has a market capitalization of $610.85 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does ViewRay have?

The company employs 267 workers across the globe.

Does ViewRay have any subsidiaries?
The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 3/26/2023 by MarketBeat.com Staff